Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation

被引:156
作者
Gimm, O
Marsh, DJ
Andrew, SD
Frilling, A
Dahia, PLM
Mulligan, LM
Zajac, JD
Robinson, BG
Eng, C
机构
[1] HARVARD UNIV, SCH MED,TRANSLAT RES LAB,HUMAN CANC GENET UNIT, DEPT MED,PROGRAM POPULAT SCI, BOSTON, MA 02115 USA
[2] UNIV SYDNEY, ROYAL N SHORE HOSP, KOLLING INST MED RES, GENET MOL LAB, ST LEONARDS, NSW 2065, AUSTRALIA
[3] EPPENDORF UNIV HAMBURG, DEPT SURG, HAMBURG, GERMANY
[4] QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA
[5] QUEENS UNIV, DEPT PAEDIAT, KINGSTON, ON K7L 3N6, CANADA
[6] ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA
[7] UNIV CAMBRIDGE, CANC RES CAMPAIGN, HUMAN CANC GENET GRP, CAMBRIDGE, ENGLAND
关键词
D O I
10.1210/jc.82.11.3902
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The autosomal dominant multiple endocrine neoplasia type 2 syndromes (MEN 2) comprise three clinically distinct entities, MEN 2A, familial medullary thyroid carcinoma and MEN 2B, which share a common clinical feature: medullary thyroid carcinoma (MTC). MEN 2B is considered to have the most aggressive form of MTC. Therefore, early detection of MEN 2B in order to prevent potentially lethal MTC is important. More than 95% of all MEN 2B cases are caused by germline mutation at codon 918 (M918T) in exon 16 of the RET proto-oncogene. In this study, we demonstrate the presence of germline codon 883 mutation (A883F) in 2 of 3 unrelated MEN 2B cases without codon 918 mutation. Our data demonstrate a novel etiologic event which may have roles in predisposition to MEN 2B when present in the germline and in the pathogenesis of sporadic MTC when somatic.
引用
收藏
页码:3902 / 3904
页数:3
相关论文
共 24 条
  • [1] BOLINO A, 1995, ONCOGENE, V10, P2415
  • [2] Borrello MG, 1995, ONCOGENE, V11, P2419
  • [4] Eng C, 1996, CANCER RES, V56, P2167
  • [5] ENG C, 1995, ONCOGENE, V10, P509
  • [6] Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO
  • [7] 2-Q
  • [8] The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis
    Eng, C
    Clayton, D
    Schuffenecker, I
    Lenoir, G
    Cote, G
    Gagel, RF
    vanAmstel, HKP
    Lips, CJM
    Nishisho, I
    Takai, SI
    Marsh, DJ
    Robinson, BG
    FrankRaue, K
    Raue, F
    Xue, FY
    Noll, WW
    Romei, C
    Pacini, F
    Fink, M
    Niederle, B
    Zedenius, J
    Nordenskjold, M
    Komminoth, P
    Hendy, GN
    Gharib, H
    Thibodeau, SN
    Lacroix, A
    Frilling, A
    Ponder, BAJ
    Mulligan, LM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19): : 1575 - 1579
  • [9] GORLIN RJ, 1968, CANCER, V22, P293, DOI 10.1002/1097-0142(196808)22:2<293::AID-CNCR2820220206>3.0.CO
  • [10] 2-R